Analysts praise intismeran’s landmark Phase III win, look to further data

Phase 2intismeranPositive

AI Analysis

Summary

Intismeran achieved positive Phase III results, with analysts anticipating further data from an upcoming Phase II renal cell carcinoma readout to evaluate the drug's broader potential across solid tumours.

Clinical Trial Data

Phase

Phase II

Importance:6/10

Sentiment:

0.70

Phase III resultsoncologysolid tumoursRCCpositive data

Related Companies

$SLDB

Read the original article

Published by Pharmaceutical Technology on August 24, 2026 10:39 AM

Read Original